21:54:42 EST Wed 18 Nov 2026
Enter Symbol
or Name
USA
CA



Vector Science and Therapeutics Corp
Symbol PAIN
Shares Issued 157,322,930
Close 2026-11-18 C$ 2.56
Market Cap C$ 402,746,701
Recent Sedar+ Documents

Vector Science, Andrews, et al. to work on peptides

2026-11-18 17:53 ET - News Release

Mr. Bill Jackson reports

ANDREWS RESEARCH & EDUCATION FOUNDATION AND VECTOR SCIENCE AND THERAPEUTICS ANNOUNCE COLLABORATION FOR THE CLINICAL EVALUATION AND DEVELOPMENT OF PEPTIDES FOR SPORTS MEDICINE AND REGENERATIVE MEDICINE APPLICATIONS

Dr. James Andrews, a world-renowned orthopedic surgeon and sports medicine pioneer, and Tommy G. Thompson, the former U.S. secretary of health and human services, four-term Governor of Wisconsin, and current chairman of Vector Science and Therapeutics Corp., have entered a collaboration with the Andrews Research & Education Foundation and Vector Science to advance the clinical evaluation of peptides for physicians' use in the practice of sports medicine and regenerative medicine. This partnership between industry and the medical research community is the first of its kind in the United States focused on musculoskeletal applications of peptides and aligns with the current movement toward much needed regulation of peptide manufacturing and distribution.

As part of the collaboration, AREF and the company will design and initiate clinical programs to evaluate the use of Vector's pharma-grade peptides for musculoskeletal applications, including approaches to accelerate repair of soft tissue following activity or injury, motivate muscle regeneration in the aging athlete, and mitigate the impact of degenerative osteoarthritis. AREF will contribute intellectual property and bench-top research from its staff at its Gulf Breeze facility, while Vector will formulate, supply and test peptides for the clinical projects using current good manufacturing practice consistent with applicable quality and regulatory requirements. Vector will also contribute specialized delivery system development, prototyping, scale-up, manufacturing development, supply, testing and analytical services in its new Mequon, Wis., facility.

"Our goal is to bring rigorous research and clinical insight to important questions in sports and regenerative medicine," said Dr. Andrews, president and chairman of the board at AREF. "By combining the foundation's research experience and clinical perspective with Vector's capabilities, we can pursue projects grounded in scientific merit, patient need and evidence. We have always led the way in developing new procedures and medical technology to help our patients. The use of peptides in medical practice is innovation that requires attention now, and we want to work closely with Vector to see that this is handled properly."

In addition, AREF and the company will develop physician education programs focused on peptide best practices and protocols. The programs will include courses for sports medicine fellows and residents, grand rounds, and multiple symposia offered through AREF's expansive sports medicine network.

"The peptide marketplace needs trust, and that trust must be built on evidence, education and quality," said Mr. Thompson. "This collaboration creates a framework to bring together established sports medicine research expertise and disciplined peptide development and manufacturing practices. We believe that this winning combination can help move the field toward a more rigorous, evidence-based approach."

Intellectual property developed through the collaboration, including new peptides, new medical applications, and intellectual property resulting from research and clinical trials, will be jointly owned by AREF and the company. Vector will lead the commercialization of new products in alignment with its highly focused, direct-to-physician marketing activities.

"The relationship with AREF represents a pivotal moment for Vector and the medical community," said Bill Jackson, chief executive officer of Vector. "We bring a focus on supply integrity, manufacturing rigour and quality assurance. Working with AREF enables us to build on these strengths through the collaborative initiatives to obtain clinical evidence, advance education and bring innovation to medical practice just as Dr. Andrews has done for decades. Together, we aim to help establish a more trusted foundation for peptide development and contribute to the development of rigorous, evidence-based standards for this emerging area in sports medicine and regenerative medicine."

Livestreamed media briefing information

Date:  Wednesday, Nov. 18, 2026

Time:  11 a.m. to 11:30 a.m. CST

Format:  live Zoom event originating in Gulf Breeze, Fla.

Preregister for event access.

Speakers:  Dr. Andrews, Mr. Thompson, Mr. Jackson, Dr. Adam Anz and Dr. Josh Hackel

Discussion moderator:  Solomon Wilcots, sports broadcaster and former NFL player, team member of Russo Partners' Sports-Health Alliance

Journalists and other audience members should preregister. Following registration, attendees will receive the information needed to access the live event.

Media interview scheduling and co-ordination

Immediately following the briefing, from 11:30 a.m. CST until 12:30 p.m. CST on Wednesday, Dr. Andrews, Mr. Thompson and other briefing participants will be available to conduct media interviews by Zoom or telephone. Interview requests and scheduling will be handled through the chat function during the Zoom event or by e-mail using vectorpr@russopartnersllc.com. Journalists who are unable to conduct interviews during this window may request additional times, and Russo Partners will manage these requests individually.

Media access to B-roll video package

A broadcast-quality B-roll package is available to media outlets. Contact Vector's media team at vectorpr@russopartnersllc.com to obtain access on-line. The package consists of footage of Vector's manufacturing team at work in Mequon, Wis., and video sound bites about the collaboration from Dr. Andrews, Mr. Thompson, Mr. Jackson and Benjamin Nelson, PhD, chief operating officer at Lyogenesis and Verlyrix.

About Dr. James Andrews

Over a career spanning more than five decades, Dr. Andrews has helped shape modern sports medicine through his work advancing arthroscopic surgical techniques and research into the prevention and treatment of knee, shoulder and elbow injuries. Dr. Andrews co-founded the American Sports Medicine Institute and the Andrews Sports Medicine and Orthopedic Center in Birmingham, Ala., and is the founder of Andrews Research and Education Foundation and the Andrews Institute in Gulf Breeze, Fla. Dr. Andrews is also the founder of Andrews Medicine. Dr. Andrews has played a leading role in research, education and the development of sports medicine specialists. His patients have included Michael Jordan, Bo Jackson, Drew Brees, Roger Clemens, Jack Nicklaus and John Smoltz. Dr. Andrews's contributions to medicine have been recognized through his induction into the Alabama Sports Hall of Fame and Louisiana Sports Hall of Fame, and the LSU Alumni Hall of Distinction, and he has received the National Athletic Trainers' Association president's award, among other honours.

About Vector Science and Therapeutics Corp.

Vector Science is a medical technology company advancing anatomically focused drug delivery technology and cGMP-manufactured Rx peptides for the sports medicine, regenerative medicine, pain management and wound care markets. Vector's peptides are made with pharmaceutical-grade active pharmaceutical ingredients from qualified suppliers and are produced under current good manufacturing practice and ISO-certified quality systems.

The company's product and intellectual property portfolio includes advanced transdermal delivery, precision catheter systems and smart wound care technologies. Vector is headquartered in Mequon, Wis.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.